Israeli Scientists Build Better Chemotherapy System (INN) ISRAEL NATIONAL NEWS) By Chana Ya´ar 05/31/12)
INN} ISRAEL NATIONAL NEWS
INN} ISRAEL NATIONAL NEWS Articles-Index-Top
Israeli scientists have figured out a more efficient, “healthier” way
to target cancer cells with chemotherapy.
Professor Daniel Wreschner at Tel Aviv University´s Department of
Cell Research and Immunology is developing antibodies that bind
solely to the cancer cells.
The proteins produced by the immune system to fight infection target
the cancer cells by binding to a protein called MUC1. The antibodies
can be used as an efficient means of delivering medication by
depositing a parcel of toxins directly into the center of the
diseased cells, Wreschner found.
His discovery showed that this method produced antibodies with a
better ability to bind to cancer cells, thus increasing the efficacy
of the antibodies and the toxins attached to them in treating the
The research, reported recently in the journal Cancer Research, was
carried out in collaboration with a team that included Dr. Nechama I.
Smorodinsky and Professor Itai Benhar of the Department of Molecular
Microbiology and Biotechnology, students Edward Pichinuk and Lotem
Weiss, and Dr. Daniel b. Rubinstein of the U.S. National Institutes
Wreschner says the findings, though encouraging, are not yet ready to
bring to the clinical treatment stage because more testing is needed.
Nevertheless, the advantage to this method has to do with the fact
that MUC1 is produced in a higher percentage of cancers.
“People who are not eligible to be treated by antibodies already on
the market could, following more research and development, likely be
eligible for this one,” he said. (IsraelNationalNews © 2012 05/31/12)
Return to Top
MATERIAL REPRODUCED FOR EDUCATIONAL PURPOSES ONLY